Back to top
more

Patterson Companies (PDCO)

(Real Time Quote from BATS)

$21.33 USD

21.33
357,385

-0.60 (-2.74%)

Updated Sep 5, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (170 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) is expected to have gained from continued recovery in Clear Aligner shipment volumes in Q4.

Hologic's (HOLX) CE-Marked Fluent System Launched in Europe

by Zacks Equity Research

Hologic (HOLX) aims to optimize, simplify and streamline hysteroscopic workflow with the latest European launch of its fluid management system.

Here's Why You Should Retain AmerisourceBergen (ABC) Now

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.

Can Diagnostics Aid Hologic (HOLX) Q1 Sales Amid Coronavirus?

by Zacks Equity Research

Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the first quarter of fiscal 2021 amid the coronavirus-led economic doldrums.

Here's Why You Should Retain AMN Healthcare (AMN) Stock Now

by Zacks Equity Research

AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.

What's in Store for Edwards Lifesciences in (EW) Q4 Earnings?

by Zacks Equity Research

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) due to a slew of regulatory approvals and buyouts.

Cardiovascular Systems' (CSII) OAS Gets CE Mark for Use in Europe

by Zacks Equity Research

Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.

Quest Diagnostics (DGX) COVID-19 Test Sales Solid, Volume Dull

by Zacks Equity Research

Quest Diagnostics (DGX) notes strong signs of the healthcare system returning to pre-pandemic levels with base testing volume gradually improving.

NEOGEN's (NEOG) New Test to Aid in Detecting Cancer-Causing Toxin

by Zacks Equity Research

NEOGEN's (NEOG) latest test is expected to simplify the process of milk testing as well as detecting lower levels of the carcinogenic metabolite Aflatoxin M1.

Integra (IART) Preliminary Q4 Reported Sales Show Recovery

by Zacks Equity Research

Integra's (IART) sales improvement in the fourth quarter is likely to have been boosted by on-going business recovery.

Thermo Fisher (TMO) Rides on End Market Growth Amid Pandemic

by Zacks Equity Research

Thermo Fisher (TMO) launches Amplitude Solution to automate high-throughput PCR-based testing and significantly expands capacity for viral transport media production in Europe.

Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results

by Zacks Equity Research

Intuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2020 result driven mainly by da Vinci procedure volume growth.

Here's Why You Should Invest in McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

DexCom (DXCM) Posts Solid Preliminary Q4 and 2020 Revenues

by Zacks Equity Research

DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

Abbott (ABT) to Expand in Booming TBI Space on New Approval

by Zacks Equity Research

If positive, Abbott's (ABT) TBI blood test result complements CT scans to help evaluate whether a suspected patient has a TBI.

Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails

by Zacks Equity Research

Phirbo's (PAHC) net vaccine sales remain robust on higher international demand for poultry vaccines.

Here's Why You Should Invest in LHC Group (LHCG) Stock Now

by Zacks Equity Research

LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.

AMN Healthcare (AMN) Releases Solid Preliminary Q4 Revenues

by Zacks Equity Research

AMN Healthcare (AMN) posts solid fourth-quarter 2020 revenue data on the back of strong demand for the company's services across its three segments.

Hologic (HOLX) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Hologic's (HOLX) impressive preliminary results for the first quarter of fiscal 2021 and regulatory approvals.

Illumina (ILMN), Helix Partner to Develop Tracking Setup in U.S.

by Zacks Equity Research

Illumina (ILMN) collaborates with Helix with support from the CDC to set up an enhanced surveillance infrastructure to track the emergence and prevalence of B.1.1.7.

National Vision (EYE) Rides on Comps Growth Amid COVID-19 Woes

by Zacks Equity Research

National Vision's (EYE) Eyeglass pumps sales are robust driven by increases in both customer transactions and average ticket.

Hologic (HOLX) Rides on Robust Preliminary Q1 Organic Sales

by Zacks Equity Research

The uptick in Hologic's (HOLX) Diagnostics sales is likely the result of increased demand for COVID-19 testing.

Hologic (HOLX) to Expand in Oncology With Biotheranostics Buyout

by Zacks Equity Research

Hologic (HOLX) aims to strengthen its Diagnostics business by foraying into the oncology adjacency space via the acquisition of Biotheranostics.

Is Patterson Companies (PDCO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (PDCO) Outperforming Other Medical Stocks This Year?